What this study is
This study proposes to carefully examine the hypothesis that human inducible pluripotent stem cells (iPSCs) can be effectively employed as a future therapeutic option for individuals with diabetic retinopathy and macular ischemia. iPSCs will be generated from the peripheral blood cells of subjects with diabetes and age matched controls. The human iPSC cells will be used to generate mesoderm cells for injection into the vitreous cavity of diabetic rodents and primate eyes. The ability of mesoderm cells to generate endothelial cells and pericytes in areas of degenerated capillaries will be examined. The human iPSCs will also be used to generate hematopoietic CD34+CD45+ cells. The combination of CD34+CD45+ cells derived from iPSCs and iPSC derived mesoderm will be examined in combination for their potentially beneficial effect to enhance the vessel formation.
What's being tested
- Generation of inducible pluripotent stem cells
Intervention · BIOLOGICAL
Generation of inducible pluripotent stem cells from peripheral blood cells.
Study details
- Sponsor
- University of Alabama at Birmingham
- Conditions
- Diabetes Complications · Diabetic Retinopathy
- Enrolling
- 20 people
- Starts
- 2018-01-11
- Est. completion
- 2027-12-31
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 21 Years – 98 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) the subject must either carry the diagnosis of diabetes or be a healthy aged control and b) the patient be willing and have the ability to cooperate with the eye exam and skin punch biopsy protocol.
You can't join if
- We will apply the following exclusion criteria: a) evidence of ongoing acute or chronic infection (HIV, Hepatitis B or C, tuberculosis); b) ongoing malignancy; c) cerebral vascular accident or cerebral vascular procedure; d) current pregnancy; e) history of organ transplantation; f) presence of a graft (to avoid any effect of the graft on inflammatory parameters; and g) patients with anemia. Subjects with AMD, glaucoma, uveitis, known hereditary degenerations or other significant ocular complications other than diabetic retinopathy will be excluded.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of Alabama at Birmingham
Birmingham, Alabama, United States
- Jennifer Moorer · Contact2053258674jmoorer@uabmc.edu
- Maria B Grant, MD · Principal investigator
Recruiting
Study team
Sponsor
University of Alabama at Birmingham
Study ID IRB-300000173
Principal investigator
Maria B Grant, MD
1954
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.